These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22914968)

  • 1. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma.
    Inubushi M; Saga T; Koizumi M; Takagi R; Hasegawa A; Koto M; Wakatuki M; Morikawa T; Yoshikawa K; Tanimoto K; Fukumura T; Yamada S; Kamada T
    Ann Nucl Med; 2013 Jan; 27(1):1-10. PubMed ID: 22914968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of
    Hasebe M; Yoshikawa K; Nishii R; Kawaguchi K; Kamada T; Hamada Y
    Int J Oral Maxillofac Surg; 2017 Oct; 46(10):1220-1228. PubMed ID: 28535963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.
    Troost EG; Bussink J; Hoffmann AL; Boerman OC; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 Jun; 51(6):866-74. PubMed ID: 20484426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers.
    Hoshikawa H; Yamamoto Y; Mori T; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Ann Nucl Med; 2014 Dec; 28(10):1020-6. PubMed ID: 25179522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
    Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET/CT with 3'-deoxy-3'-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy.
    Saga T; Koizumi M; Inubushi M; Yoshikawa K; Tanimoto K; Fukumura T; Miyamoto T; Nakajima M; Yamamoto N; Baba M
    Nucl Med Commun; 2011 May; 32(5):348-55. PubMed ID: 21326122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma.
    Abgral R; Le Roux PY; Rousset J; Querellou S; Valette G; Nowak E; Turzo A; Tissot V; Marianowski R; Salaün PY
    Nucl Med Commun; 2013 Jun; 34(6):551-6. PubMed ID: 23587836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ( 18 ) F-FLT PET and ( 18 ) F-FDG PET for detection of cervical lymph node metastases in head and neck cancers.
    Hoshikawa H; Kishino T; Mori T; Nishiyama Y; Yamamoto Y; Inamoto R; Akiyama K; Mori N
    Acta Otolaryngol; 2012 Dec; 132(12):1347-54. PubMed ID: 22992199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
    Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
    Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor.
    Zhao K; Luo XM; Zhou SH; Liu JH; Yan SX; Lu ZJ; Yang SY; Lin LL; Dong MJ
    Cancer Biother Radiopharm; 2012 Dec; 27(10):685-93. PubMed ID: 22834634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy.
    Romesser PB; Qureshi MM; Shah BA; Chatburn LT; Jalisi S; Devaiah AK; Subramaniam RM; Truong MT
    Ann Nucl Med; 2012 Aug; 26(7):527-34. PubMed ID: 22610386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.